Quantum BioPharma Ltd.
QNTM
$6.30
$0.060.96%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.49% | 3.67% | 6.49% | -66.62% | -47.54% |
| Depreciation & Amortization | -7.69% | -17.71% | -87.65% | -89.37% | -89.44% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 298.82% | 26.24% | -30.76% | -75.90% | -76.50% |
| Operating Income | -298.82% | -26.24% | 30.76% | 75.90% | 76.50% |
| Income Before Tax | -230.36% | -254.96% | 38.94% | 79.00% | 73.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -230.36% | -254.96% | 38.94% | 79.00% | 73.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -62.65% | 163.59% | -- | -- | -- |
| Net Income | -284.39% | -261.12% | 43.32% | 80.88% | 77.32% |
| EBIT | -298.82% | -26.24% | 30.76% | 75.90% | 76.50% |
| EBITDA | -324.79% | -28.28% | 14.54% | 74.05% | 73.80% |
| EPS Basic | -17.46% | -137.22% | 46.64% | 81.22% | 77.95% |
| Normalized Basic EPS | -104.79% | 19.24% | 37.61% | 81.27% | 85.91% |
| EPS Diluted | -17.46% | -137.22% | 46.66% | 80.77% | 77.95% |
| Normalized Diluted EPS | -104.79% | 19.24% | 37.61% | 81.27% | 85.91% |
| Average Basic Shares Outstanding | 227.25% | 52.21% | 6.23% | 1.77% | 2.87% |
| Average Diluted Shares Outstanding | 227.25% | 52.21% | 6.23% | 1.77% | 2.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |